E A Baker1, F G Bergin, D J Leaper. 1. North Tees General Hospital, Stockton on Tees TS19 8PE, UK. drlizbaker@yahoo.co.uk
Abstract
AIMS: To plasminogen activator system (PAS) consists of the plasminogen activators (urokinase (uPA) and tissue-type (tPA) plasminogen activators), the uPA receptor (uPAR), and the plasminogen activator inhibitors (PAI-1 and PAI-2). Plasminogen activators activate plasminogen to plasmin, which can break down extracellular matrix (ECM) components. Vascular endothelial growth factor (VEGF) is a mitogen for endothelial cells and is involved in angiogenesis. VEGF has been shown to upregulate uPA and this may facilitate tumour angiogenesis further. METHODS: PAS components and VEGF were determined by enzyme linked immunosorbent assay (ELISA) in paired colorectal tumour and normal tissue (n = 50) and correlated with pathological staging. RESULTS: uPA, uPAR, PAI-1, and VEGF values were significantly higher in tumour tissue (for example, tumour uPA: median, 2.3 (range, 0.1-6.7) ng/mg protein v normal uPA: median, 0.2 (range, 0-2.6) ng/mg protein). tPA was significantly higher in normal mucosa and there was no difference in PAI-2. uPA, uPAR, PAI-1, and VEGF values significantly correlated with each other and with Dukes's staging (uPA in adenomas: median, 0.42 (range, 0.1-1.2) ng/mg protein; upA in Dukes's B tumours: median, 2.1 (range, 0.4-4.3) ng/mg protein; and uPA in Dukes's D tumours: median, 4.0 (range, 3.7-4.2) ng/mg protein) and lymphatic invasion. In addition PAI-1 also correlated with tumour size and differentiation. CONCLUSION: The involvement of the PAS and VEGF in colorectal cancer appears to be complex. uPA, uPAR, PAI-1, and VEGF were upregulated in tumour tissue and this correlated with Dukes's staging and lymphatic invasion.
AIMS: To plasminogen activator system (PAS) consists of the plasminogen activators (urokinase (uPA) and tissue-type (tPA) plasminogen activators), the uPA receptor (uPAR), and the plasminogen activator inhibitors (PAI-1 and PAI-2). Plasminogen activators activate plasminogen to plasmin, which can break down extracellular matrix (ECM) components. Vascular endothelial growth factor (VEGF) is a mitogen for endothelial cells and is involved in angiogenesis. VEGF has been shown to upregulate uPA and this may facilitate tumour angiogenesis further. METHODS: PAS components and VEGF were determined by enzyme linked immunosorbent assay (ELISA) in paired colorectal tumour and normal tissue (n = 50) and correlated with pathological staging. RESULTS:uPA, uPAR, PAI-1, and VEGF values were significantly higher in tumour tissue (for example, tumouruPA: median, 2.3 (range, 0.1-6.7) ng/mg protein v normal uPA: median, 0.2 (range, 0-2.6) ng/mg protein). tPA was significantly higher in normal mucosa and there was no difference in PAI-2. uPA, uPAR, PAI-1, and VEGF values significantly correlated with each other and with Dukes's staging (uPA in adenomas: median, 0.42 (range, 0.1-1.2) ng/mg protein; upA in Dukes's B tumours: median, 2.1 (range, 0.4-4.3) ng/mg protein; and uPA in Dukes's D tumours: median, 4.0 (range, 3.7-4.2) ng/mg protein) and lymphatic invasion. In addition PAI-1 also correlated with tumour size and differentiation. CONCLUSION: The involvement of the PAS and VEGF in colorectal cancer appears to be complex. uPA, uPAR, PAI-1, and VEGF were upregulated in tumour tissue and this correlated with Dukes's staging and lymphatic invasion.
Authors: S Nakata; K Ito; M Fujimori; K Shingu; S Kajikawa; W Adachi; I Matsuyama; S Tsuchiya; M Kuwano; J Amano Journal: Int J Cancer Date: 1998-04-17 Impact factor: 7.396
Authors: C F Sier; H W Verspaget; G Griffioen; J H Verheijen; P H Quax; G Dooijewaard; P A De Bruin; C B Lamers Journal: Gastroenterology Date: 1991-12 Impact factor: 22.682
Authors: S J Mandriota; G Seghezzi; J D Vassalli; N Ferrara; S Wasi; R Mazzieri; P Mignatti; M S Pepper Journal: J Biol Chem Date: 1995-04-28 Impact factor: 5.157
Authors: M M Skelly; A Troy; M J Duffy; H E Mulcahy; C Duggan; T G Connell; D P O'Donoghue; K Sheahan Journal: Clin Cancer Res Date: 1997-10 Impact factor: 12.531
Authors: S Ganesh; C F Sier; M M Heerding; J H van Krieken; G Griffioen; K Welvaart; C J van de Velde; J H Verheijen; C B Lamers; H W Verspaget Journal: Br J Cancer Date: 1997 Impact factor: 7.640
Authors: Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx Journal: Neoplasia Date: 2007-11 Impact factor: 5.715
Authors: Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse Journal: Cancer Immunol Immunother Date: 2008-01-10 Impact factor: 6.968
Authors: Kamil Torres; Anna Torres; Grzegorz J Staśkiewicz; Andrzej Chrościcki; Tadeusz Loś; Ryszard Maciejewski Journal: Surg Endosc Date: 2008-12-06 Impact factor: 4.584
Authors: Liesbeth M Veenendaal; Hangqing Jin; Sophia Ran; Lawrence Cheung; Nora Navone; John W Marks; Johannes Waltenberger; Philip Thorpe; Michael G Rosenblum Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205